ストックスクリーナーアプリを入手
24.06
1.51%
-0.37
プレマーケット:
23.97
-0.09
-0.37%
前日終値:
$24.43
開ける：
$24.6
24時間の取引高:
10.74M
Relative Volume:
1.04
時価総額：
$11.04B
収益：
$5.06B
当期純損益:
$-2.22B
株価収益率:
-4.134
EPS:
-5.82
ネットキャッシュフロー:
$-3.96B
1週間 パフォーマンス:
-15.70%
1か月 パフォーマンス:
-6.16%
6か月 パフォーマンス:
-52.15%
1年 パフォーマンス:
-80.13%
1日の値動き範囲:
$23.70
$24.92
1週間の範囲:
$23.70
$28.52
52週間の値動き範囲:
$23.15
$170.47
Moderna Inc Stock (MRNA) Company Profile
MRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.06 | 11.04B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.82 | 130.98B | 11.10B | -988.90M | -978.00M | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 64.65B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
622.93 | 39.39B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.55 | 34.32B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
232.25 | 28.03B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
Kovitz Investment Group Partners LLC Has $326,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Combo flu and COVID-19 shot shows promise in new Moderna study - LiveNOW from FOX
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 - marketscreener.com
Moderna Vaccine Study - Tulsa World
Moderna study shows immune response in older adults for a combo flu and COVID-19 shot - Value The Markets
Cantor Fitzgerald L. P. Acquires Shares of 16,961 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Dimensional Fund Advisors LP Has $69.34 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
BLI Banque de Luxembourg Investments Takes Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Northern Trust Corp Buys 354,871 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
GraniteShares adjusts Moderna ETP in upcoming consolidation By Investing.com - Investing.com UK
This Week's Healthcare Earnings: Moderna, CVS, Hims & Hers - Law360
Moderna, Pharma Stocks Fall as FDA Names Industry Critic as Top Vaccine Regulator - Barron's
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1 - The Globe and Mail
Redburn Atlantic Adjusts Moderna Price Target to $53 From $52, Maintains Neutral Rating - marketscreener.com
69,708 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by Banque Transatlantique SA - MarketBeat
Public Employees Retirement Association of Colorado Trims Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
mRNA Vaccines: Evolving Pipelines Across Infectious Disease, Oncology & Rare Disorders - openPR.com
Moderna, Inc. (NASDAQ:MRNA) Stock Position Increased by Lido Advisors LLC - MarketBeat
Price T Rowe Associates Inc. MD Has $44.62 Million Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Envestnet Asset Management Inc. Lowers Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
On the Move: Moderna's Cronin Moves to Medtronic Diabetes - O'Dwyer's PR
Ex-Moderna brand chief Kate Cronin joins Medtronic Diabetes as marketing lead - Medical Marketing and Media
Moderna Sharpens Pipeline Focus As COVID-19 Vaccine Demand Ebbs In Q1 - Barchart.com
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by PDT Partners LLC - MarketBeat
The Manufacturers Life Insurance Company Acquires 267,990 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Stock Crumbles As Vaccine Troubles Rattle Its Topline - MSN
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Pinebridge Investments L.P. - MarketBeat
Moderna Q1 Earnings Ahead: Analysts expect loss amid increased regulatory scrutiny - MSN
Moderna, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MRNA - ACCESS Newswire
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Aquatic Capital Management LLC - MarketBeat
UBS Analyst Lowers Price Target for MRNA, Maintains Buy Rating | - GuruFocus
XTX Topco Ltd Decreases Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Barclays Lowers Price Target on Moderna (MRNA) to $40.00 | MRNA Stock News - GuruFocus
Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes - insights.citeline.com
Susquehanna Fundamental Investments LLC Invests $16.04 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna (MRNA) Price Target Lowered by RBC Capital | MRNA Stock News - GuruFocus
Moderna (MRNA) Target Price Cut by RBC Capital Amid Financial Up - GuruFocus
Moderna (NasdaqGS:MRNA) Reports Decrease in Q1 Revenue and Net Loss - Yahoo Finance
Moderna faces long-term threat from NIH’s universal vaccine initiative, Jefferies says - Proactive Investors
Moderna (MRNA) Downgraded as Financial Strains Emerge - GuruFocus
UBS Adjusts Price Target on Moderna to $70 From $78, Maintains Buy Rating - marketscreener.com
Moderna (MRNA) Analyst Maintains Rating but Lowers Price Target - GuruFocus
UBS Revises Price Target for Moderna (MRNA) Due to Vaccine Uncer - GuruFocus
Moderna (MRNA) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Moderna Earnings Top Estimates. Why the Stock Is Dropping. - Barron's
Moderna price target lowered to $28 from $32 at RBC Capital - TipRanks
Moderna, Inc. (NASDAQ:MRNA) Q1 2025 Earnings Call Transcript - Insider Monkey
Berenberg holds Moderna stock with $30 target amid cost cuts - Investing.com
Berenberg holds Moderna stock with $30 target amid cost cuts By Investing.com - Investing.com UK
State of Tennessee Department of Treasury Sells 27,726 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Inc (MRNA) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Cost ... - Yahoo Finance
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
0.60%
2.05%
大文字化:
|
ボリューム (24 時間):